Related Experiment Video

Updated: Aug 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The role of pleiotropic effects of statins in dementia

M Crisby1

  • 1Neurotec Department, Karolinska Institutet, Stockholm, Sweden. milita.crisby@neurotec.ki.se

Acta Neurologica Scandinavica. Supplementum
|July 27, 2006
PubMed

Insights

Statins, used to lower cholesterol and reduce heart disease risk, may also impact dementia development by affecting the mevalonate pathway. This review explores statins' biological effects on dementia pathogenesis.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • High serum cholesterol is linked to ischemic heart disease and may influence brain amyloid beta-peptide interactions.
  • Statins inhibit HMG-CoA reductase, the key enzyme in cholesterol synthesis, effectively lowering LDL and VLDL levels.
  • Cardiovascular mortality and morbidity have decreased due to statin use over the past decade.

Purpose of the Study:

  • To review the biological effects of statins on the pathogenesis of dementia.
  • To discuss how statins regulate processes involved in dementia development.

Main Methods:

  • Literature review of in vivo and in vitro research on statins.
  • Analysis of the mevalonate pathway and its intermediates.
  • Examination of cholesterol's role in brain function and disease.

Main Results:

  • Statins reduce cholesterol synthesis by inhibiting HMG-CoA reductase.
  • Evidence suggests statins have broader biological effects beyond cholesterol reduction.
  • Inhibition of the mevalonate pathway by statins may influence dementia pathogenesis.

Conclusions:

  • Statins possess pleiotropic effects, impacting processes beyond lipid-lowering.
  • Further research is needed to fully understand statins' role in dementia.
  • Statins' influence on the mevalonate pathway warrants investigation for potential therapeutic applications in dementia.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...